Share This Page
Drugs in ATC Class A07EC
✉ Email this page to a colleague
Drugs in ATC Class: A07EC - Aminosalicylic acid and similar agents
| Tradename | Generic Name |
|---|---|
| AZULFIDINE | sulfasalazine |
| AZULFIDINE EN-TABS | sulfasalazine |
| SULFASALAZINE | sulfasalazine |
| S.A.S.-500 | sulfasalazine |
| DIPENTUM | olsalazine sodium |
| >Tradename | >Generic Name |
Market dynamics and patent landscape for ATC Class A07EC (aminosalicylic acid and similar agents)
ATC Class A07EC (amino-salicylic acid and similar agents) is a mature, off-patent market in most jurisdictions for core actives used in inflammatory bowel disease (IBD). Competitive pressure is driven by generic and branded-me-too erosion after loss of composition and method protection, with ongoing patent value mostly concentrated in formulation differentiation, dosing regimens, and regional process/impurity control. The patent landscape remains material for risk-managed launches of delayed-release and controlled-release mesalamine products, and for lifecycle entries that exploit regulatory exclusivities and Orange Book listing-dependent patent coverage for each specific strength and dosage form.
A07EC also includes “similar agents” beyond generic mesalamine, which shifts the patent picture to platform-like chemistry and drug-product buildouts: prodrug/acid-protected derivatives, new delivery coatings, and granule architectures that change release location and timing in the GI tract.
What patents protect aminosalicylic acid (mesalamine) and similar A07EC drugs in the US?
Featured snippet answer: US protection for A07EC products is usually split across (1) drug substance patents, (2) formulation and delivery system patents, and (3) use patents (dose regimen or specific therapeutic indications). For older mesalamine, most composition patents are expired; current value tends to sit in granular delayed-release and controlled-release product families and in process/impurity patents.
Typical patent categories seen in A07EC estates
-
Composition of matter (drug substance)
Often expired for long-established mesalamine actives. -
Formulation and dosage form
- Delayed-release coatings that protect drug from upper GI pH.
- Controlled-release matrices or multi-particulate granules.
- Particle size distribution, excipients, and coating weights that drive release profile.
-
Method-of-use
- Maintenance dosing schedules (timing, titration).
- Specific population subtyping (though enforceability depends on claim construction and FDA labeling language).
-
Manufacturing/process
- Granulation and coating processes.
- Solvent systems, drying parameters, and impurity thresholds.
-
Polymorph/hydrate or salt forms More common where “similar agents” include derivative actives.
Enforcement footprint that matters for launch planning
- Patent enforcement is usually asserted at the level of product-specific formulation and NDA/BLA listing rather than broad drug-substance claims.
- For generic entry, the actionable set is typically the patents listed in the Orange Book for the specific NDA and dosage form. Where multiple patents cover different strengths or release technologies, Paragraph IV exposure is “granular” to the product lineup.
When does mesalamine patent protection lose exclusivity and enable generic entry?
Featured snippet answer: For classic mesalamine products, generic entry typically occurs after expiration of composition and major formulation patents, often well before the present for first-wave products. Remaining exclusivity leverage tends to come from later life-cycle filings on specific release technologies and from regulatory exclusivities that may delay entry for particular product/NDA families.
Timeline mechanics used in the A07EC market
- Drug substance: earliest to expire for older actives.
- Formulation: often the last major barrier, because delayed-release delivery systems are harder to copy without claim overlap.
- Method-of-use: can extend exclusivity where claim language remains narrow and aligned to labeling.
What this means for market dynamics
- After major formulation patents expire, the market usually shifts to:
- price compression,
- pharmacy switching to low-cost equivalents,
- and continued brand activity through “next-generation” formulations and regional channel management.
- In many A07EC segments, the “effective exclusivity” is the last-to-expire formulation patent that still blocks at least one economically relevant strength/dosing.
How many Orange Book patents cover A07EC mesalamine products, and which ones are usually decisive?
Featured snippet answer: The Orange Book footprint for a single mesalamine product family can include multiple listed patents, but only a subset typically drive generic blocking because generic applicants target listed patents most likely to be enforced. For lifecycle-protected delivery systems, listed patents can be numerous across strengths.
Why the “count” can mislead
- Multiple patents can be listed that cover:
- the same formulation with different claim scopes,
- process variants,
- and use variants.
- For litigation and launch planning, what matters is whether patents are:
- timely (not expired or disclaimed),
- relevant to the proposed generic formulation,
- and assertable against the generic’s release profile.
Launch-risk pattern for generics
- If a generic can design around claim constraints (coating type, granule architecture, excipient selection), the practical blocking set can shrink even when the list looks large.
- If the generic is required to match dissolution and release characteristics closely, formulation-dependent patents remain the most material.
Which companies challenge mesalamine patents via Paragraph IV certifications?
Featured snippet answer: US generic and specialty generics commonly file Paragraph IV challenges against mesalamine product families once Orange Book protections are near expiration. The specific list of challengers is product-family dependent, and it concentrates around the most economically sized strengths and delivery technologies.
Market behavior seen in A07EC challenges
- Challengers often target:
- widely prescribed strengths,
- once- or multi-daily dosing formats,
- and delivery systems where formulation patents most restrict generic replication.
- Litigation and settlement patterns typically track to a compromise:
- delayed launch for the challenger,
- cross-licensing or branded supply arrangements,
- or market-entry timing tied to patent expiry milestones.
What A07EC formulation patents protect delayed-release and controlled-release mesalamine?
Featured snippet answer: In A07EC, the most litigated “last mile” IP is usually drug product technology for delayed-release/controlled-release mesalamine. These patents cover granular structures, coating architectures, release kinetics, and manufacturing parameters.
Common claim themes for A07EC delivery systems
- Multi-particulate granules with specific coating thickness and composition.
- Acid-resistant coating materials designed to shift release from stomach to distal small intestine or colon.
- Matrix composition controlling release rate.
- Specific excipient sets tied to dissolution behavior and stability.
How these patents affect generic design
Generic developers usually need to:
- hit dissolution release curves that the labeling and clinician expectations demand,
- while staying outside claim scope on:
- coating composition ranges,
- granule size distributions,
- and manufacturing steps.
The practical outcome is that “same active, different release profile” is the primary litigation axis.
Do method-of-use patents matter for A07EC maintenance therapy?
Featured snippet answer: Method-of-use patents can matter, but they typically have a smaller role than formulation patents because enforced method claims depend on medical practice alignment with the labeled regimen. Generic label-corrections or carve-outs can also reduce enforceability.
Typical method-of-use structures
- Maintenance dosing schedule claims.
- Indication-aligned claims tied to relapse prevention.
- Dose escalation or stepped regimens.
Enforcement reality for lifecycle value
- If the approved label already prescribes broad dosing ranges, method claims become harder to enforce without tight claim-to-label mapping.
- If a product’s lifecycle strategy created a distinct labeled regimen later, those method claims can carry more weight.
How does biosimilar risk apply to A07EC?
Featured snippet answer: Biosimilar risk is not a direct driver in A07EC because the class is largely small-molecule aminosalicylates (mesalamine and related derivatives) rather than biologics. Competitive differentiation is largely through drug product formulation and ANDA paragraph IV landscape, not biosimilars.
Where “similar agents” can change the picture
If “similar agents” include prodrugs or distinct small-molecule derivatives, competition still follows ANDA and patent lifecycle dynamics. Biosimilar pathways do not typically apply.
What litigation and settlements typically occur for mesalamine IP?
Featured snippet answer: A07EC litigation usually resolves through settlement agreements that delay generic launches for a period correlated to the most relevant formulation/use patents. These settlements typically involve a scheduled launch date and sometimes a carve-out of strengths or dosage forms.
Litigation’s role in market timing
- Branded companies manage:
- channel continuity,
- tender procurement where contract timing matters,
- and patient switching through continued discounting.
- Generic entry is often timed to coincide with patent expiry for specific dosage forms.
Settlement patterns used in A07EC
- Partial settlements covering only certain strengths.
- Carve-outs for technically distinct formulations.
- Agreements that allow market entry for some SKUs earlier than others.
What is the FDA regulatory status of A07EC drugs and how does it drive exclusivity?
Featured snippet answer: FDA status in A07EC is dominated by 505(b)(2) and 505(j) ANDAs for generics. Exclusivity is usually tied to:
- patent expiration (Orange Book),
- and any applicable regulatory exclusivities per NDA history.
Practical consequences
- Generic applicants route via ANDA and certify against listed patents.
- Exclusivity in practice is mostly a function of:
- listed patents that remain active,
- and litigation/settlement-driven launch timing.
How strong is the patent estate for the top A07EC product families?
Featured snippet answer: Patent strength is concentrated in the most recent lifecycle families that built differentiable release technology. For older mesalamine brands, estates are generally weak to moderately strong depending on outstanding formulation/process patents still listed for specific strengths/dosage forms.
Strength drivers in A07EC
- Claim scope tied to specific drug product build and release characteristics.
- Multiple listed patents per SKU, including formulation and manufacturing.
- Remaining active process and impurity constraints that are difficult to design around.
Weakness drivers
- Expired broad drug-substance patents.
- Overlap between multiple patents leading to early narrowing or invalidation risk.
- Generic ability to match release profiles via alternative excipients/coatings.
How does ATC A07EC compare with other GI anti-inflammatory classes on patent duration and pricing pressure?
Featured snippet answer: Compared with newer oncology or immunology categories, A07EC has shorter effective duration for core actives because early composition patents expired long ago. The market still supports mid-term premium pricing when formulation patents extend life-cycle differentiation.
Comparative dynamics
- A07EC behaves like a typical mature small-molecule GI class:
- rapid generic adoption once formulation barriers fall,
- and brand persistence through differentiated delivery technologies rather than long-standing exclusivities.
What generic entry risks exist for A07EC delayed-release mesalamine?
Featured snippet answer: Launch risk centers on whether the generic’s formulation can:
- avoid infringement of the listed formulation/delivery system patents, and
- stay within dissolution and release specifications without claim overlap.
Key infringement vectors
- Coating chemistry and thickness ranges.
- Granule size and release kinetics.
- Manufacturing processes defining impurity control or intermediate steps.
Timing risks
- Even with “near expiration” patents, settlement can delay entry.
- If a patent is re-litigated or extended via continuation filings, timing can shift.
What formulations are protected by A07EC patents?
Featured snippet answer: The protected formulation space in A07EC is concentrated in delayed-release oral products (and in some cases rectal formulations depending on the product family) where release timing and location are central to efficacy and where granular/matrix technologies are claimable.
Form factor buckets that tend to map to different IP sets
- Oral delayed-release capsules/tablets.
- Multi-matrix or multi-particulate granule systems.
- Rectal forms (where present in the product family).
- Different strengths linked to different coating compositions or process parameters.
Key Takeaways
- A07EC is a mature small-molecule market where most core mesalamine composition IP is largely expired; remaining patent value is concentrated in formulation and delivery-system patents tied to specific release technologies and strengths.
- Generic launch timing is driven by the Orange Book patent-by-patent landscape and by Paragraph IV litigation/settlement outcomes, with risk focused on claim overlap for delayed-release/controlled-release performance.
- Biosimilar risk is not a meaningful driver in A07EC because the class is not biologic-based; competition instead hinges on ANDA pathways and drug-product differentiation.
- Patent strength is highest for the newest lifecycle families where release technology is demonstrably distinct and enforceable; it is weakest for older first-generation mesalamine brands once major formulation patents roll off.
FAQs
1) What happens to mesalamine pricing after formulation patents expire?
After the last enforceable formulation patents expire for economically relevant strengths, generic adoption typically compresses net price via pharmacy substitution and tender pressure, with branded firms relying on remaining lifecycle SKUs or channel contracts.
2) How do ANDA Paragraph IV certifications work for A07EC drugs?
ANDA filers certify to each listed Orange Book patent for the relevant NDA and strength, selecting Paragraph IV for patents they contend are invalid, unenforceable, or not infringed.
3) Which types of mesalamine patent claims are most vulnerable in generic litigation?
Formulation claims with broad ranges that fail to tie to a specific, reproducible product build, and method claims that are not tightly anchored to label-specific regimens, tend to face the highest invalidity or non-infringement pressure.
4) Do process patents block generic mesalamine even when formulation seems similar?
Yes, if process claims are properly listed and the generic must use a substantially similar process to meet quality and release requirements, process patents can add an infringement vector beyond the finished product structure.
5) Are “similar agents” in A07EC protected differently from mesalamine?
Yes. Derivative or prodrug “similar agents” often have distinct drug-substance and solid-state chemistry protection, shifting some value away from classic mesalamine formulation families toward chemistry and derivative-specific process/build claims.
References
- FDA. (n.d.). Drugs@FDA database. U.S. Food and Drug Administration.
- FDA. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
- Hatch-Waxman Act, 21 U.S.C. § 355 and related provisions. (n.d.). United States Code.
More… ↓
